ht-102
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2023 (NCT06744686)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07245953 | Phase 2 | Nov 5, 2025 | Government of China, Southern Medical University |
| NCT07088133 | N/A | Aug 1, 2025 | Fudan University |
| NCT07183306 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2024 | Government of China |
| NCT06744686 | Phase 1 | Jun 12, 2023 | Government of China |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 2 | 2023 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1